Seeking Alpha

Inovio, Chelsea struggle after Feuerstein mention

  • Shares of Inovio Pharmaceuticals (INO -7.3%) and Chelsea Therapeutics (CHTP -10%) are notably lower on the session.
  • They have one thing in common today: They are both mentioned by TheStreet's Adam Feuerstein in his Biotech Stock Mailbag column.
  • On INO: "The technology upon which the company's vaccine candidates are based is more than 30 years old and has never proven to be effective in clinical trials. INO's management team is exceptionally promotional and 85% of the company's stock is held by retail investors, according to S&P CapitalIQ."
  • On CHTP: "I will say Zheng and I probably agree on Northera almost as much as we disagree. CHTP is in for a tough fight at the Jan. 14 panel because the Northera data are far from confidence inspiring," Feuerstein writes, referencing SA contributor Nick Zheng (see Zheng's recent article here).
Comments (29)
  • Tri Duong
    , contributor
    Comments (1454) | Send Message
     
    Unfortunately for Mr. Feuerstein, clinical trials resulted in positive outcome for almost everyone. I wonder if anyone even bother to check facts anymore.
    3 Jan, 12:20 PM Reply Like
  • fourms_2000
    , contributor
    Comments (8) | Send Message
     
    These blogs prey on uninformed investors. Think about it. Blogs are written by people that try to be a jack-of-all-companies by weeding through a couple of reports and selecting just enough information to make readers think they actually know more than the staff at the company under scrutiny. Sad that they are able to pull off this charade for a few investors that are easily swayed.

     

    Moreover, nobody in their right mind would be saying what Dr. Kim has recently reported unless there was a substantial amount of data to back up said statements.

     

    Each broadcast has it's own motive. Good investors have to have adequate knowledge of their own to know who to believe.
    3 Jan, 12:56 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    I wonder if anyone bothers to read articles anymore, either. In this article, Feuerstein states he is actually bullish on CHTP.
    3 Jan, 01:26 PM Reply Like
  • Stephen Tips
    , contributor
    Comments (276) | Send Message
     
    tduong11:

     

    I agree, this is total nonsense: If anyone knows anything about Dr. J. J. Kim, he certainly is not a phony PR man.

     

    Due diligence from analysts more qualified than Feuerstein can be found here:

     

    .http://bit.ly/1amoXet
    3 Jan, 01:47 PM Reply Like
  • findingomega
    , contributor
    Comments (53) | Send Message
     
    Perhaps they ignore the facts. Stop clicking on AF. Ignore him ignoring facts.
    11 Jun, 09:39 AM Reply Like
  • pagreen1966
    , contributor
    Comments (573) | Send Message
     
    (INO) was a good play while it lasted. Bought into it last February at $0.52 and sold it at $1.50.

     

    There are better plays this year including (TNXP), (NBS) and (DARA).
    3 Jan, 12:23 PM Reply Like
  • doc2014
    , contributor
    Comments (2) | Send Message
     
    I am a physician. I rarely invest in individual companies, preferring to stay in well-diversivied ETFs. This is one of a handful of companies that I do invest in. The science is excellent and the preclinical data are absolutely stunning.
    3 Jan, 12:55 PM Reply Like
  • britecrawl
    , contributor
    Comments (46) | Send Message
     
    Gosh, Adam must be smarter than all the sceintists at Roche that agreed to fork over the 485 mil over the long run.....perhaps he ought to change professions and run to Switzerland and correct all those folks that did the due diligence for Roche.........
    3 Jan, 12:56 PM Reply Like
  • piem18848
    , contributor
    Comments (115) | Send Message
     
    The great scientific mind with no education in medicine or science strikes again with comments on CHTP. Just what major does Adam have?
    3 Jan, 08:48 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    He's in favor of CHTP. Bullish. If you're disagreeing with him, that must mean you're shorting it.
    3 Jan, 09:08 PM Reply Like
  • genoa93
    , contributor
    Comments (76) | Send Message
     
    And of course no mention about:
    - Moore Capital Management recent buying of INO shares (http://bit.ly/1bE15zW)
    - strong insider buying
    Mr. Feuerstain, pls, try to be fair sometimes....
    3 Jan, 01:05 PM Reply Like
  • omcdac
    , contributor
    Comments (70) | Send Message
     
    INO is worth to keep long. This technology is impressive.
    3 Jan, 01:11 PM Reply Like
  • dmallik
    , contributor
    Comments (28) | Send Message
     
    I only wish I had the clout to manipulate stock prices as Adam did. Could have made a years income in a couple days; 50% on the January $3 puts today and probably as much on the calls in a week.
    3 Jan, 02:17 PM Reply Like
  • steady888
    , contributor
    Comments (83) | Send Message
     
    I like reading Adam's pieces but come on Dude! You can't just turn on a damn dime like that. I can understand the challenges that CHTP has but why do you bring them out now unless you were not already on record in thinking they will get approval. You got to have more responsibility than just spew things out your mounth that cost investors when your opinion is widely reported. Good Grief!!
    3 Jan, 02:23 PM Reply Like
  • normandemma@hotmail.com
    , contributor
    Comments (13) | Send Message
     
    You begin to wonder,the whole system seems to be set up to take advantage of the little guy. Individuals get to say anything they want with no punishment. Big groups buy shorts and are able to control the stock value of a company for no other reason than to make themselves money, it is O.K, totally legal. They make the rules
    3 Jan, 04:15 PM Reply Like
  • MacCBOE
    , contributor
    Comments (32) | Send Message
     
    how does one buy a short ? ("Big groups buy shorts") ?
    11 Feb, 10:36 PM Reply Like
  • omcdac
    , contributor
    Comments (70) | Send Message
     
    Inovio has a number of promising pre-clinical and early stage vaccine candidates, my take is that investors are squarely focused on the company's lead clinical candidate VGX-3100. VGX-3100 is a synthetic DNA vaccine being tested in a mid-stage trial as a possible treatment for cervical dysplasia. Inovio is expected to release topline results from the study by mid-2014.
    3 Jan, 04:14 PM Reply Like
  • doc2014
    , contributor
    Comments (2) | Send Message
     
    Inovios technology is preclinical in humans, but its shown to work in vivo in animals. This alosne should give a big boost of confidence in INO.

     

    http://bit.ly/1lFCu3b
    3 Jan, 04:14 PM Reply Like
  • William Meyers
    , contributor
    Comments (119) | Send Message
     
    I am long INO but know it is speculative until there is an FDA approval. Often Feuerstein is right, but I don't think a $500 million or so cap ex for INO is excessive given the potential of the technology if it works in humans as well as it works in test tubes. The idea that retail investors are wrong and institutional investors are right is poor thinking: institutional investors tend to be risk-averse and some (pension funds) have rules against investing in sub $10 stocks. I understand the risk-rewards scenario at Inovio and accept the risks. When trial data comes out, I'll look at the statistics carefully. The price drop today was most likely caused by profit-taking among those who bought the stock at under $1 or even under $0.50, then waited until 2014 to sell so the capital gains would be in 2014 instead of in 2013. Can't blame people for locking in some profit.
    3 Jan, 04:31 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    I think some people are putting too much credence into what Adam Feuerstein writes in relation to market movements. I mean, is it not possible that today's action was the result of something else besides this article? Both CHTP and INO were down yesterday, before the article came out.

     

    INO has dropped to where it was ...... a week ago. It's not like it has taken a cataclysmic drop. And as for CHTP, if you actually read his article, he said he was BULLISH on it.

     

    I don't always agree with AF but I do enjoy reading his articles because I think it's good to have an honest broker to help gauge investment strategies. I've gone against him and have done well; I've also taken his advice and have saved future losses.

     

    Look at it this way: an investment blogger should not have the power to significantly move the share price of a solid company by writing an article on it. Either something else has moved the share price, or the company really isn't that solid in the first place.
    3 Jan, 05:00 PM Reply Like
  • russleehowe
    , contributor
    Comments (54) | Send Message
     
    Here's the scoop: Start a TV show. Act crazy. Get a big audience. Short a stock. Then trash it. Laugh all the way to the bank. CHTP is the latest example of this. I've seen several of these over the past year. It's always the same story.
    3 Jan, 06:36 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    Feuerstein was bullish on CHTP. So using your advice, should I short it, too, since he doesn't have the correct background?
    3 Jan, 08:33 PM Reply Like
  • russleehowe
    , contributor
    Comments (54) | Send Message
     
    Do your own research and make your own decisions. All I am saying is that he pumps stocks and then writes negative articles. This isn't the first time he's done this. I would say about once every couple of months this pattern repeats itself. You figure it out.
    3 Jan, 09:17 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    I do my own homework, thank you very much. It just doesn't seem that you did, because AF has been in favor of CHTP the whole time.
    3 Jan, 09:58 PM Reply Like
  • russleehowe
    , contributor
    Comments (54) | Send Message
     
    You keep accusing me of making illogical statements and saying I don't do my own research. This isn't one of those sports comment sections where opposing fans trash each other. Get a life.
    For your information I made 257% return in 2012 and over 150% last year. My December was up 38% and this week alone I am up 40%. Not bad for someone being accused of being a amateur. I didn't say you don't do your own homework. And I didn't say do the opposite of what AF does. Maybe you need to take a couple of courses in reading comprehension and logic. AF was in favor of CHTP before he was against it. Sounds familiar? When he's in favor of a stock it goes up and when he trashes it it goes down, taking his followers with it. Good night and good-bye.
    3 Jan, 11:40 PM Reply Like
  • P Man
    , contributor
    Comments (1141) | Send Message
     
    Again, when did he trash it?
    4 Jan, 12:39 AM Reply Like
  • russleehowe
    , contributor
    Comments (54) | Send Message
     
    Feuerstein graduated from Emory University with a bachelor's degree in political science. OK, do you really want to take investment advice from a political science major? Maybe you don't need to have a PhD in biology or biochemistry to make money investing in bio tech, but it's a good idea to do your own research and not follow this guy.
    3 Jan, 06:46 PM Reply Like
  • 17147502
    , contributor
    Comments (8) | Send Message
     
    Today I bought CHTP, I think there is more chance for the drug to be approved than being rejected. I think holding two masters degree in engineering and science provides me the knowledge to do a better DD than AF or ...

     

    Win or lose is ok with me since I did my own DD
    4 Jan, 01:54 AM Reply Like
  • gkbest
    , contributor
    Comment (1) | Send Message
     
    As a research microbiologist with a Ph.D. and nearly 100 publications, I am confident in my ability to recognize scientific fraud as opposed to promising (if unproven) research. INO is devoted to the latter and a long-term investment in them is warranted with the risk portion of your funds. Adam Feurstein is not someone I would go to for scientific evaluation of research projects. Dr. Kim's credentials are solid and his work has been amply recognized. Who to believe is not a difficult choice in this matter.
    4 Jan, 08:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|